Opinion

Video

Venetoclax-Based Treatment Clinical Trial Updates

Author(s):

Yuliya P.L Linhares, MD,Josie Montegaard, MSN, AGPCNP-BC

Yuliya Linhares, MD, discusses the CLL14 study, which is looking at venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Related Videos
A panel of 3 experts on CML
Related Content
Illustration of a man with curly hair, wearing round glasses.
November 7th 2024

The Pathway of Cancer is Fraught with Anxiety

Chester Freeman
As a patient with chronic lymphocytic leukemia, I recently gleaned three new insights from my oncologist and phlebotomist.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Illustration of red blood cells.
October 10th 2024

Jaypirca Plus Venclexta With or Without Rituxan May Be Beneficial in r/r CLL

Alex Biese
A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
Illustration of a man with round glasses and a goatee.
October 7th 2024

My Bitter Chemotherapy Pills for Chronic Lymphocytic Leukemia

Chester Freeman
I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.
Photo courtesy of Mike Peters.
October 4th 2024

Mike Peters of the Alarm in Remission, Broadway Star Gavin Creel Dies and More

Alex Biese Ashley Chan
From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.